Taztia XT — Class II drug recall D-145-2013
Terminated recall by Watson Pharmaceuticals, reported 2013-02-13, distributed nationwide. Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing.
| Recall number | D-145-2013 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Watson Pharmaceuticals, Parsippany, NJ, United States |
| Recall initiated | 2012-12-18 |
| Classified | 2013-02-04 |
| Reported by FDA | 2013-02-13 |
| Terminated | 2014-07-30 |
| Distributed | Nationwide (US) |
| Quantity | 3,040 bottles |
| Reason classes | specification failure |
| NDC | 62037-0700-90 |
| Lot numbers | 512146A |
| Expiration dates | 2014-01-31 |
Product
Taztia XT(diltiazem HCI extended release capsules, USP, Once-A-Day Dosage, 360 mg, 90 Capsules per bottle, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880, Distributed by: Watson Pharma, NDC 62037-700-90.
Reason for recall
Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-145-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.